Skip to main content

Table 2 5-year overall- and disease free survival rates depending on subgroups of prognostic factors (* p-values of log-rank tests comparing survival times between subgroups)

From: Sequencing chemotherapy and radiotherapy in locoregional advanced breast cancer patients after mastectomy – a retrospective analysis

    5-year OS rate   5-year DFS rate  
    % p* % p*
All patients n (%) 212 (100 %) 53   46  
Sequencing of chemo- and radiotherapy n (%) SEQ 86 (40.6) 53.2 0.04 56 0.03
  SW 70 (33) 38.1   32  
  SIM 56 (26.4) 64.2   50  
Age n (%) age ≤ 50 41 (19.3) 59.4 0.9 52.2 0.6
  age > 50 171 (80.7) 52.2   45.3  
histological type n (%) ductal-invasiv 158 (74.5) 54.2 0.6 47.8 0.6
  ductal-lobular 35 (16.5) 47.6   45.2  
  other 19 (9) 46.8   0  
pT n (%) pT1 33 (15.6) 70.6 0.06 70.8 0.03
  pT2 90 (42.5) 59.8   44.4  
  pT3 41 (19.3) 54.2   45.1  
  pT4 48 (22.6) 31.4   36.8  
pN n (%) pN0 48 (22.6) 65.7 0.1 52.2 0.1
  pN1 35 (16.5) 53.8   53.4  
  pN2-3 129 (60.8) 48.5   42.1  
LVI n (%) yes 77 (36.3) 40.4 0.01 34.9 0.001
  no 135 (63.7) 59.4   52.9  
G n (%) G1 5 (2.4) 33.1 0.04 53.3 0.3
  G2 89 (42) 63.2   49.5  
  G3 118 (55.7) 46.2   44.6  
ECS n (%) yes 110 (51.9) 44.8 0.04 40.2 0.01
  no 102 (48.1) 61.8   52.2  
Receptor (ER and/or PR) n (%) positive 158 (74.5) 56.7 0.07 48.1 0.2
  negative 54 (25.5) 41.3   40.0  
R n (%) R0 197 (92.9) 53.3 0.8 47.3 0.04
  R+ 15 (7.1) 56.7   35.0  
V n (%) yes 194 (91.5) 0 0.03 0 0.002
  no 18 (8.5) 55.0   48.3  
RT region n (%) parasternal fields (in 28.3% created) not separately considered THW +SIA 148 (69.8) 52.2 0.4 51.9 0.4
  THW alone 17 (8) 72.8   0  
  SIA alone 47 (22.2) 50.6   36.6